Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Klotho beta (KLB) is a type I transmembrane protein that functions as an obligate co-receptor for the endocrine fibroblast growth factors FGF19 and FGF21. It primarily expressed in the liver and pancreas, and plays a crucial role in regulating metabolism, particularly bile acid synthesis and glucose uptake. KLB forms a complex with FGFRs to mediate downstream signaling, impacting various cellular processes. Mutations or dysregulation of KLB have been linked to hypogonadotropic hypogonadism and functional diarrhea.
KLB acts as an obligate co-receptor for specific endocrine fibroblast growth factors (FGFs) such as FGF19 and FGF21. It forms a ternary complex with FGFRs (fibroblast growth factor receptors) to mediate signaling, enhancing binding affinity between these FGFs and their respective receptors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Klotho beta protein (KLB).